Pfizer Provides U.S. Regulatory Update On Prevnar 13™ Vaccine
- Details
- Category: Pfizer
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13™, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company's candidate 13-valent pneumococcal conjugate vaccine.
Sanofi-aventis to Acquire Chattem Inc. Creating a Strong U.S. Consumer Healthcare Platform
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Chattem, Inc. (NASDAQ: CHTT) have entered into a definitive agreement under which sanofi-aventis is to acquire 100 percent of the outstanding shares of Chattem in a cash tender offer for $93.50 per share, or approximately $1.9 billion.
FDA Approves SPIRIVA® HandiHaler® for the Reduction of COPD Exacerbations
- Details
- Category: Pfizer
Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Sanofi Pasteur to Develop & Commercialize Vaccine to Prevent Staphylococcus infections
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, it has entered into an exclusive, world-wide licensing agreement with Syntiron to develop and commercialize its prophylactic vaccine against Staphylococcus, including Methicillin-Resistant Stapyhylococcus aureus or MRSA.
GSK publishes speaking, consulting fees paid to US healthcare professionals
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline published a list of fees paid between April 1 and June 30 to U.S. healthcare professionals for speaking and consulting services. GSK will update this list quarterly going forward.
Array BioPharma and Amgen Partner in Type 2 Diabetes
- Details
- Category: Amgen
Array BioPharma Inc. (Nasdaq: ARRY) and Amgen Inc.(Nasdaq: AMGN) today announced that they entered into an agreement granting Amgen exclusive worldwide rights to Array's small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes.
Takeda and Pfizer to Co-Promote Takeda's Actos® for the Treatment of Type 2 Diabetes in China
- Details
- Category: Pfizer
Takeda Pharmaceutical Company Limited ("Takeda") and Pfizer Inc. ("Pfizer") announced that they have entered into an agreement under which Pfizer in China will co-promote Takeda's Actos® (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in China.
More Pharma News ...
- Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems
- GSK and Intercell form strategic alliance to develop and commercialise innovative vaccines
- Pfizer Extends Commitment to Help Unemployed Americans
- Physicians More Likely To Report Drug Safety Information Through Electronic Health Records System
- Novartis Tasigna® trial shows superior results to Glivec®
- Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab
- Novo Nordisk starts phase 1 trial with oral insulin analogue